Enzalutamide Active in Low-, Intermediate-Risk Prostate Cancer - Elko Daily Free Press
6/27/2022 12:00:00 AM2 years 10 months ago
by Physician’s Briefing Staff
by Physician’s Briefing Staff
MONDAY, June 27, 2022 (HealthDay News) -- For patients with low- or intermediate-risk localized prostate cancer, enzalutamide monotherapy plus active surveillance (AS) is well tolerated and induces a significant treatment
Physicians Briefing Staff MONDAY, June 27, 2022 (HealthDay News) -- For patients with low- or intermediate-risk localized prostate cancer, enzalutamide monotherapy plus active surveillance (AS) is w… [+1874 chars]
full article...